ADA BOSTON

A one-time update of insulin-delivery parameters using patient data was no more effective at regulating blood glucose levels than using a patient’s insulin pump settings to initialize the artificial pancreas system, according to study findings presented here.
See Also

In a randomized,

En spruta med insulinproducerande celler i låret. Det kan vara framtidens behandling för typ 1-diabetes. Och det behöver inte heller vara så avlägset om man får tro forskarna på diabeteskonferensen i USA.

In the Veteran's Affairs Diabetes Trial (VADT) of mainly older men with poor glycemic control, those who were randomized to receive about 5 years of intensive vs standard glycemic therapy had a lower incidence of cardiovascular events, but no improved survival during a median 9.8-year follow-up, new

Den europeiska läkemedelsmyndigheten EMA har inlett en granskning av tre läkemedelssubstanser som används för att behandla typ 2-diabetes, enligt pressmeddelande från Läkemedelsverket.

Granskningen ska utvärdera risken att substanserna orsakar diabetesketoacidos, som kan utvecklas då personer har

Rapport från ADA (American Diabetes Association) mötet, 5-9 juni, 2015,

Boston, Massachusetts, US

Amerikanska diabetesmötet är ett av diabetesvärldens största möten i antalet deltagare och antalet presentationer. I år deltog ett 50-tal svenskar. Flertalet av dessa hade egen vetenskaplig

Insatser i den friska befolkningen räddar flest hjärtliv

Dödligheten i hjärt-kärlsjukdomar har minskat i Sverige. De förbättrade siffrorna beror till största delen på förändrade riskfaktorer i den friska befolkningen, och i mindre utsträckning på behandlingar och förändringar hos de som redan är

Insatser i den friska befolkningen räddar flest hjärtliv

Dödligheten i hjärt-kärlsjukdomar har minskat i Sverige. De förbättrade siffrorna beror till största delen på förändrade riskfaktorer i den friska befolkningen, och i mindre utsträckning på behandlingar och förändringar hos de som redan är

ADA Boston

BOSTON — Among US Medicare beneficiaries with type 2 diabetes, out-of-pocket expenses diminish adherence to medication and may end up increasing overall healthcare costs in the long run, a new study finds.

The results, from an analysis of Medicare claims data for 2006–2009, were

ADA Boston

(Reuters Health) - Intranasal glucagon can safely and effectively treat hypoglycemia in children with type 1 diabetes (T1D), according to new findings presented at the American Diabetes Association's annual meeting in Boston.

Currently, intramuscular injections that must be mixed before

ADA Boston

Lilly Insulin Tops Sanofi's Lantus in T2DM Trials

(Reuters) - A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials

ADA Boston. 75th ADA Meeting. Looking back to Science in Diabetes last 20 years

The discovery of insulin in 1921 and the availability of home blood glucose monitoring in 1981 perhaps represent the greatest advances thus far in the world of diabetes. But in the past 20 years, numerous incremental

ADA Boston.

Already 1994 the 4 S Study, the first study was published, a Scandinavian study with 4444 patients for 5 years showing effects of simvastatin on hard end points, heart infarctions – and in diabetic patients there was a 55% drop of heart attacks. The lipid hypothesis is accepted, and

ADA Boston.

Already 1994 the 4 S Study, the first study was published, a Scandinavian study with 4444 patients for 5 years showing effects of simvastatin on hard end points, heart infarctions – and in diabetic patients there was a 55% drop of heart attacks. The lipid hypothesis is accepted, and

ADA Boston

Latinos who worry about having enough food to eat, so called food insecurity, report having a poorer diet and exhibit worse glycemic control ,HbA1c, than tose who are not worried about having sufficient food to surivive, according to a study

These findings suggest that food insecurity

ADA Boston

Gut-hormone-based mewdication used to treat diabetes, such as GLP-1-receptor agonists, have also been show to reduce body weight. Researchers have ben working to understand how.

This study sheds light on how these medications alter the brain´s response to food, possibly reducing

ADA BOSTON 

Type 1 diabetes patients younger than 40 may be candidates for statin use, as guidelines recommend after age 40, researchers suggested.

Under the American Heart Association/American College of Cardiology definition,

• the 10-year cardiovascular risk was about 5% for type 1 diabetes patients

ADA Boston.

Treatment with sitagliptin, a DPP4-inhibitor, versus placebo for median 3 years in 14 671 patients with type 2 diabetes and established cardiovascular (CV) disease showed non-inferiority for the primary composite CV endpoint of the trial evaluating CV outcomes (TECOS) in the

ADA Boston

From fiercemedicaldevices.com

Today's Top News

Medtronic touts data in support of FDA approval of the latest MiniMed glucose monitor

Medtronic presented data in support of FDA approval of its MiniMed 640G glucose monitor and pump at the ongoing annual meeting of the American Diabetes

Tidningen DiabetologNytt skickas i början av denna vecka ut till 4000 medlemmar i Svensk Förening för Diabetologi.

Du som väntar på Din tidning eller Du som bara vill läsa den på www

Gå in på www.dagensdiabetes.se

så ligger den där överst till vänster, klickbar och utan lösenord

eller gå in på nedan www så

Press release from Sanofi 

ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

Full results for ELIXA study presented at American Diabetes Association's 75th Scientific Sessions -

Paris, France - June 8, 2015 - Sanofi announced today the

 ADA Boston

Diabetes education and support are needed throughout a persons´ life, not just at diagnosis. It has always been acknowledged as a key part of diabetes care.

Scientific evidence supports a structure for education. We know that education works. Research has shown that diabetes education and